Healthcare provider profile · identity verified

Matthew Ling, MD

Internal Medicine · KALAMAZOO, MI · NPI 1760419246

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	455	110
Atorvastatin Calcium	Atorvastatin Calcium	455	135
Levothyroxine Sodium	Levothyroxine Sodium	446	108
Lisinopril	Lisinopril	292	79
Rosuvastatin Calcium	Rosuvastatin Calcium	267	89
Simvastatin	Simvastatin	131	38
Losartan Potassium	Losartan Potassium	129	36
Pravastatin Sodium	Pravastatin Sodium	127	34
Furosemide	Furosemide	126	30
Sertraline Hcl	Sertraline Hcl	117	29
Omeprazole	Omeprazole	106	29
Eliquis	Apixaban	104	25
Gabapentin	Gabapentin	103	30
Metformin Hcl	Metformin Hcl	97	27
Pantoprazole Sodium	Pantoprazole Sodium	89	26
Metoprolol Succinate	Metoprolol Succinate	87	30
Montelukast Sodium	Montelukast Sodium	85	17
Ozempic	Semaglutide	85	16
Tamsulosin Hcl	Tamsulosin Hcl	85	24
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	84	12
Fluticasone Propionate	Fluticasone Propionate	83	25
Alendronate Sodium	Alendronate Sodium	82	27
Allopurinol	Allopurinol	80	18
Metformin Hcl Er	Metformin Hcl	76	25
Alprazolam	Alprazolam	75	24
Albuterol Sulfate Hfa	Albuterol Sulfate	74	34
Hydrochlorothiazide	Hydrochlorothiazide	73	23
Famotidine	Famotidine	67	19
Metoprolol Tartrate	Metoprolol Tartrate	64	18
Trazodone Hcl	Trazodone Hcl	61	16
Duloxetine Hcl	Duloxetine Hcl	57	21
Olmesartan Medoxomil	Olmesartan Medoxomil	52	11
Bupropion Xl	Bupropion Hcl	51	15
Ezetimibe	Ezetimibe	47	20
Finasteride	Finasteride	47	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	43	19
Carvedilol	Carvedilol	40	11
Atenolol	Atenolol	39	suppressed
Cephalexin	Cephalexin	39	28
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	36	11
Trulicity	Dulaglutide	36	suppressed
Fentanyl	Fentanyl	35	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	34	11
Mounjaro	Tirzepatide	33	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	33	11
Potassium Chloride	Potassium Chloride	30	suppressed
Citalopram Hbr	Citalopram Hydrobromide	28	suppressed
Clopidogrel	Clopidogrel Bisulfate	28	suppressed
Januvia	Sitagliptin Phosphate	28	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	28	suppressed
Pregabalin	Pregabalin	28	suppressed
Synthroid	Levothyroxine Sodium	27	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	26	21
Meloxicam	Meloxicam	24	suppressed
Ramipril	Ramipril	24	suppressed
Valsartan	Valsartan	23	suppressed
Ventolin Hfa	Albuterol Sulfate	23	11
Meclizine Hcl	Meclizine Hcl	22	suppressed
Azelastine Hcl	Azelastine Hcl	21	suppressed
Baclofen	Baclofen	21	suppressed
Dulera	Mometasone/Formoterol	21	suppressed
Naproxen	Naproxen	21	suppressed
Colestipol Hcl	Colestipol Hcl	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Raloxifene Hcl	Raloxifene Hcl	20	suppressed
Valacyclovir	Valacyclovir Hcl	20	12
Jardiance	Empagliflozin	19	suppressed
Nystatin	Nystatin	19	suppressed
Oxycodone Hcl	Oxycodone Hcl	19	suppressed
Prednisone	Prednisone	19	15
Tramadol Hcl	Tramadol Hcl	19	suppressed
Warfarin Sodium	Warfarin Sodium	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Tizanidine Hcl	Tizanidine Hcl	18	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	17	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	17	suppressed
Lansoprazole	Lansoprazole	17	suppressed
Telmisartan	Telmisartan	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	16	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Lovastatin	Lovastatin	16	suppressed
Clonazepam	Clonazepam	15	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	15	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Clonidine	Clonidine	14	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	14	suppressed
Loperamide	Loperamide Hcl	14	suppressed
Methimazole	Methimazole	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Sodium Chloride	0.9 % Sodium Chloride	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Testosterone	Testosterone	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Aripiprazole	Aripiprazole	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Phenobarbital	Phenobarbital	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Benztropine Mesylate	Benztropine Mesylate	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Propranolol Hcl Er	Propranolol Hcl	12	suppressed
Torsemide	Torsemide	12	suppressed
Wegovy	Semaglutide	12	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	11	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	11	suppressed
Rybelsus	Semaglutide	11	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error